Highly sensitive droplet digital polymerase chain reaction for <i><scp>BCR</scp>::</i><scp><i>ABL1</i> messenger RNA</scp> identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment‐free remission

Lü, Ling; Kok, Chung Hoow; Dang, Phuong; Branford, Susan; Saunders, Verity A.; Shanmuganathan, Naranie; Ross, David M.; Hughes, Timothy P.; Yeung, David T.

doi:10.1111/bjh.18277

Br J Haematol

2022

DOI: 10.1111/bjh.18277

|View full text |Cite

Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment‐free remission

Ling Lü

Chung Hoow Kok

Phuong Dang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients

Kockerols,

Valk,

Janssen

et al. 2024

European J of Haematology

View full text Add to dashboard Cite

Precise and reliable predictive parameters to accurately identify chronic myeloid leukemia (CML) patients who can successfully discontinue their tyrosine kinase inhibitor (TKI) treatment are lacking. One promising parameter is depth of molecular response measured by BCR::ABL1 digital PCR (dPCR). The aim of this study was to validate a previously described prediction cutoff of 0.0023%IS and to assess the value of dPCR for treatment‐free remission (TFR) prediction in relation to other clinical parameters. A droplet‐based dPCR assay assessed BCR::ABL1 %IS prior to TKI discontinuation. The primary endpoint was molecular recurrence (MolR) by 36 months. A total of 186 patients from Canada, Germany, and the Netherlands were included. In patients with a first TKI discontinuation attempt (n = 163), a BCR::ABL1 dPCR < and ≥0.0023%IS had a MolR probability of 33% and 70%, respectively. Patients treated less than 6 years with a BCR::ABL1 dPCR <0.0023%IS had a MolR probability of 31%. After correction for treatment duration, both high dPCR value and the use of imatinib (vs. second‐generation TKI) were significantly associated with a higher risk of MolR (HR of 3.66, 95%CI 2.06–6.51, p < .001; and 2.85, 95%CI 1.25–6.46, p = .013, respectively). BCR::ABL1 dPCR was not associated with TFR outcome after second TKI discontinuation, however, with the limitation of a small number of patients analyzed (n = 23). In conclusion, BCR::ABL1 digital PCR based on the cutoff of 0.0023%IS is a valuable predictive tool to identify CML patients with a high probability of TFR success after first TKI discontinuation, including patients treated for less than 6 years.

show abstract

Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients

Kockerols,

Valk,

Janssen

et al. 2024

European J of Haematology

View full text Add to dashboard Cite

show abstract

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

Pagani,

Shanmuganathan,

Dang

et al. 2023

Blood

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) patients who are eligible for treatment-free remission (TFR) may still relapse after tyrosine kinase inhibitor (TKI) cessation. There is a need for accurate predictors of outcome to enable patients with a favorable profile to proceed while avoiding futile attempts. Sensitive detection of residual disease in total leukocytes at treatment cessation is associated with relapse, but is not highly discriminatory, likely because it is a composite measure of residual leukemia derived from different cell lineages whereas only some lineages are relevant for relapse. We prospectively measured BCR::ABL1 DNA as a predictive yes/no binary test in five cellular fractions from 48 patients meeting conventional criteria for TKI discontinuation. The median BCR::ABL1 DNA level was higher in granulocytes and in T cells, but not in other lineages, in patients who relapsed. In the 40 patients undergoing a first TFR attempt we defined three groups with differing relapse risk: granulocytes-positive (100%), granulocytes-negative/T cells-positive (67%), and granulocytes-negative /T cells-negative (25%). These data show the critical importance of lineage-specific assessment of residual disease in the selection of patients who can attempt TFR with a high expectation of success, and concurrently defer patients who have a high probability of relapse.

show abstract

A traffic light for TFR by lineage-specific MRD

Breccia

2023

Blood

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment‐free remission

Cited by 3 publications

References 14 publications

Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients

Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

A traffic light for TFR by lineage-specific MRD

Contact Info

Product

Resources

About